Zeit für ein Browserupdate

IE6 not supported.

Keine sichere Verbindung.

no ssl-connection established.


Kopfbereich

Logo

THIS INFORMATION IS FOR NON-US HEALTHCARE PROVIDERS ONLY

Polycythemia Vera

Polycythemia vera (PV) is a Rare Disease of the blood-building cells in the bone marrow primarily resulting in a chronic increase of red blood cells (erythrocytes), thereby decreasing the flowability of blood.

Polycythemia vera (British English: Polycythaemia vera) is a clonal hematopoetic stem cell disease; its cause is still unknown. The hyperplasia of erythropoetic cells is the most important issue. The increased production of erythrocytes leads to elevated hematocrit and hemoglobin counts. At the same time, there is often a rise in granuolopoesis and megakaryopoesis.
The annual incidence rate of new cases to be found in corresponding literature is between 0.7 and 2.7 per 100,000 inhabitants; most of the people diagnosed are between the ages of 50 and 70. The average age of patients being diagnosed for the first time is 62[1]; the disease is much less common among younger patients[2].

Treatment for PV is administered in consideration of age and risk factors. All PV patients require treatment as a rule. The treatment focuses on minimizing the risk of developing arterial and venous thromboses. In order to safeguard quality of life, it is important to treat microcirculatory disorders and constitutional symptoms decisively.

Find more information on aoporphan.com …

References
[1] Finazzi, G. and T. Barbui, Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev, 2005. 19(5): p. 243-52
[2] Tefferi, A., L.A. Solberg, and M.N. Silverstein, A clinical update in polycythemia vera and essential thrombocythemia. Am J Med, 2000. 109(2): p. 141-9.